J.P. Morgan analyst Anupam Rama maintained a Buy rating on First Tracks Biotherapeutics Inc yesterday and set a price target of $30.00. The company’s shares closed yesterday at $17.18.Meet Samuel – Your Personal Investing ProphetStart a conversation with TipRanks’ trusted, data-backed investment intelligence
Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Rama covers the Healthcare sector, focusing on stocks such as Sarepta Therapeutics, Erasca, and Zai Lab. According to TipRanks, Rama has an average return of 21.9% and a 50.20% success rate on recommended stocks.
Currently, the analyst consensus on First Tracks Biotherapeutics Inc is a Strong Buy with an average price target of $38.33, which is a 123.11% upside from current levels. In a report released on May 15, Barclays also maintained a Buy rating on the stock with a $40.00 price target.
